Pasithea Therapeutics Corp (KTTA) Stock Analysis

Verdict: WATCH (do not buy)

Net-cash valuation discount provides downside cushion for PAS-004 clinical catalysts, but massive authorized share expansion limits upside.

Investment score: 46/100

Analysis as of

Is Pasithea Therapeutics Corp stock worth reviewing? The TradeMates thesis

TradeMates rates KTTA as WATCH: a negative Enterprise Value biotech backed by ~28 months of cash runway, offset by complete pre-revenue risk and severe dilution capacity.

7-factor investment score

Pasithea Therapeutics Corp opportunities and risks

What speaks for KTTA

What speaks against KTTA

Peers and competitors

Trailing-twelve-month ratios
TickerP/EP/SEV/EBITDAGross marginNet marginFCF yield
KTTAn/a0.0x1.2x0.0%0.0%-100.4%
MCRBn/a10.3xn/a29.5%-1192.9%-263.3%
ESLAn/a0.0xn/a0.0%0.0%-51.6%
ACUTn/a23.3xn/a100.0%-1680.0%-52.4%
ALLRn/a52.1xn/a107.5%-3575.1%-76.7%
KYNB0.1x3.8x0.4x18.2%3967.8%-218.1%
Peer mediann/a10.3xn/a29.5%-1192.9%-76.7%

Frequently asked questions about Pasithea Therapeutics Corp (KTTA)

Is KTTA stock a good investment?

The TradeMates model rates Pasithea Therapeutics Corp as WATCH (do not buy) with an investment score of 46/100. TradeMates rates KTTA as WATCH: a negative Enterprise Value biotech backed by ~28 months of cash runway, offset by complete pre-revenue risk and severe dilution capacity. This is algorithmic model output, not personal investment advice.

Is KTTA stock a buy?

The TradeMates model verdict for KTTA is WATCH (do not buy) with an investment score of 46/100. Treat this as a model signal to review, not a personal buy recommendation.